PMID- 23244564
OWN - NLM
STAT- MEDLINE
DCOM- 20130417
LR  - 20170220
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 56
IP  - 1
DP  - 2013 Jan 10
TI  - Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using
      fragment-based methods and structure-based design.
PG  - 15-30
LID - 10.1021/jm301448p [doi]
AB  - Myeloid cell leukemia 1 (Mcl-1), a member of the Bcl-2 family of proteins, is
      overexpressed and amplified in various cancers and promotes the aberrant survival
      of tumor cells that otherwise would undergo apoptosis. Here we describe the
      discovery of potent and selective Mcl-1 inhibitors using fragment-based methods
      and structure-based design. NMR-based screening of a large fragment library
      identified two chemically distinct hit series that bind to different sites on
      Mcl-1. Members of the two fragment classes were merged together to produce lead
      compounds that bind to Mcl-1 with a dissociation constant of <100 nM with
      selectivity for Mcl-1 over Bcl-xL and Bcl-2. Structures of merged compounds when 
      complexed to Mcl-1 were obtained by X-ray crystallography and provide detailed
      information about the molecular recognition of small-molecule ligands binding
      Mcl-1. The compounds represent starting points for the discovery of clinically
      useful Mcl-1 inhibitors for the treatment of a wide variety of cancers.
FAU - Friberg, Anders
AU  - Friberg A
AD  - Department of Biochemistry, Vanderbilt University School of Medicine, 2215
      Garland Avenue, 607 Light Hall, Nashville, Tennessee 37232-0146, USA.
FAU - Vigil, Dominico
AU  - Vigil D
FAU - Zhao, Bin
AU  - Zhao B
FAU - Daniels, R Nathan
AU  - Daniels RN
FAU - Burke, Jason P
AU  - Burke JP
FAU - Garcia-Barrantes, Pedro M
AU  - Garcia-Barrantes PM
FAU - Camper, DeMarco
AU  - Camper D
FAU - Chauder, Brian A
AU  - Chauder BA
FAU - Lee, Taekyu
AU  - Lee T
FAU - Olejniczak, Edward T
AU  - Olejniczak ET
FAU - Fesik, Stephen W
AU  - Fesik SW
LA  - eng
GR  - DP1 CA174419/CA/NCI NIH HHS/United States
GR  - S10 RR025677/RR/NCRR NIH HHS/United States
GR  - RC2A148375/RC/CCR NIH HHS/United States
GR  - RC2 CA148375/CA/NCI NIH HHS/United States
GR  - P50CA098131/CA/NCI NIH HHS/United States
GR  - DP1 OD006933/OD/NIH HHS/United States
GR  - 1S10RR025677-01/RR/NCRR NIH HHS/United States
GR  - P50 CA098131/CA/NCI NIH HHS/United States
GR  - DP1OD006933/OD/NIH HHS/United States
GR  - DP1CA174419/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20121217
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Ligands)
RN  - 0 (Myeloid Cell Leukemia Sequence 1 Protein)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Small Molecule Libraries)
RN  - 0 (bcl-X Protein)
SB  - IM
CIN - J Med Chem. 2013 Jan 10;56(1):13-4. PMID: 23265190
MH  - Antineoplastic Agents/*chemistry
MH  - Crystallography, X-Ray
MH  - Databases, Factual
MH  - Drug Design
MH  - Humans
MH  - Indoles/chemical synthesis/chemistry
MH  - Ligands
MH  - Magnetic Resonance Spectroscopy
MH  - Molecular Docking Simulation
MH  - Molecular Structure
MH  - Myeloid Cell Leukemia Sequence 1 Protein
MH  - Protein Binding
MH  - Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors/chemistry
MH  - Small Molecule Libraries/*chemistry
MH  - Structure-Activity Relationship
MH  - bcl-X Protein/chemistry
PMC - PMC3646517
MID - NIHMS429806
OID - NLM: NIHMS429806
OID - NLM: PMC3646517
EDAT- 2012/12/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2012/12/19 06:00
PHST- 2012/12/19 06:00 [entrez]
PHST- 2012/12/19 06:00 [pubmed]
PHST- 2013/04/19 06:00 [medline]
AID - 10.1021/jm301448p [doi]
PST - ppublish
SO  - J Med Chem. 2013 Jan 10;56(1):15-30. doi: 10.1021/jm301448p. Epub 2012 Dec 17.